PKS Advisory Services LLC Takes $63,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

PKS Advisory Services LLC bought a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 17,650 shares of the company’s stock, valued at approximately $63,000.

A number of other hedge funds have also recently bought and sold shares of AQST. Intech Investment Management LLC bought a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $90,000. Charles Schwab Investment Management Inc. boosted its holdings in Aquestive Therapeutics by 4.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 203,540 shares of the company’s stock worth $1,014,000 after buying an additional 9,268 shares in the last quarter. Quantbot Technologies LP acquired a new position in Aquestive Therapeutics in the third quarter worth approximately $135,000. BNP Paribas Financial Markets increased its holdings in shares of Aquestive Therapeutics by 252.2% in the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock valued at $94,000 after buying an additional 13,481 shares in the last quarter. Finally, MetLife Investment Management LLC increased its holdings in shares of Aquestive Therapeutics by 86.3% in the third quarter. MetLife Investment Management LLC now owns 36,096 shares of the company’s stock valued at $180,000 after buying an additional 16,716 shares in the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Lake Street Capital cut their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. Cantor Fitzgerald initiated coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective on the stock. Alliance Global Partners reiterated a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a report on Monday, March 10th. Finally, Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $10.57.

Aquestive Therapeutics Stock Performance

AQST stock opened at $3.12 on Thursday. The firm has a 50 day simple moving average of $2.99 and a 200 day simple moving average of $3.97. Aquestive Therapeutics, Inc. has a 52 week low of $2.24 and a 52 week high of $5.80. The stock has a market cap of $308.48 million, a P/E ratio of -6.93 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, March 5th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The business had revenue of $11.87 million for the quarter, compared to the consensus estimate of $13.11 million. Sell-side analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.